• Home
  • NEW DAY MEDICINE
  • 3 (27) 2019
  • 72 -3 (27/2) 2019 — Khamdamova M.T., Kenzhaeva Z.O., — MODERN ASPECTS OF DIAGNOSTICS AND TREATMENT OF PREMENSTRUAL SYNDROME

72 -3 (27/2) 2019 — Khamdamova M.T., Kenzhaeva Z.O., — MODERN ASPECTS OF DIAGNOSTICS AND TREATMENT OF PREMENSTRUAL SYNDROME

MODERN ASPECTS OF DIAGNOSTICS AND TREATMENT OF PREMENSTRUAL SYNDROME

Khamdamova M.T., Bukhara State Medical institute named after Abu Ali Ibn Sina.

Kenzhaeva Z.O., Bukhara State Medical institute named after Abu Ali Ibn Sina.

 Navruzova N.O. Bukhara State Medical institute named after Abu Ali Ibn Sina.

Resume,

The variety of symptoms of premenstrual disorders is due to various reasons, but the trigger is the same – it is ovulation. The most effective approach to suppressing ovulation with premenstrual syndrome is the use of oral contraceptives containing drospirenone as the progestogen component.

Keywords: premenstrual syndrome, oral contraceptives, drospirenone, midiana, dimia,

First page

269

Last page

271

For citation: Khamdamova M.T., Kenzhaeva Z.O., Navruzova N.O. Modern aspects of diagnostics and treatment of premenstrual syndrome//New Day in Medicine 3(27)2019 269-271 https://cutt.ly/ybx27kM

List of References

  1. ACOG Committee on Practice Bulletins–Gynecology. ACOG practice bulletin: no 15: Premenstrual syndrome. Obstet. Gynecol. 2000; 95(4, Suppl.): 1-9.
  2. Brown J., O’Brien P.M., Marjoribanks J., Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev. 2009; (2): CD001396.
  3. Coffee A.L., Kuehl T.J., Willis S., Sulak P.J. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am. J. Obstet. Gynecol. 2006; 156: 1311-9.
  4. Fathizadeh N., Ebrahimi E., Valiani M., Tavakoli N., Yar M.H. Evaluating the effect of magnesium and magnesium plus vitamin B6 supplement on the severity of premenstrual syndrome. Iran J. Nurs. Midwifery Res. 2010; 15(Suppl. 1): 401-405.
  5. Frank R.T. The hormonal causes of premenstrual tension. Arch. Neurol. Psychiatry. 1931; 26: 1053-1057.
  6. Grady-Weliky T.A. Clinical practice. Premenstrual dysphoric disorder. N. Engl. J. Med. 2003; 348: 433-8.
  7. Hahn P.M., Van Vugt D.A., Reid R.L. A randomized, placebo- controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology. 1995; 20: 193­209.
  8. Joffe H., Petrillo L.F., Viguera A.C., Gottshcall H., Soares C.N., Hall J.E., Cohen L.S. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. J. Clin. Psychiatry. 2007; 68(12): 1954-62.
  9. Kuznetsova I.V., Konovalov V.A. Prolonged combined oral contraceptive containing drospirenone in the treatment of premenstrual syndrome. Problems of reproduction. 2008; 4: 28-31.
  10. Leminen H., Paavonen J.PMS and PMDD. Duodecim. 2013; 129(17): 1756-63.
  11. Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev. 2012; (2):
  12. O’Brien P.M., B?ckstr?m T., Brown C., Dennerstein L., Endicott J., Epperson C.N. et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch. Womens Ment. Health. 2011; 14(1): 13-21.
  13. Oelkers W., Helmerhorst F.M., Wuttke W. Effect of an oral contraceptives containing drospirenone on the rennin- angiotensin-aldosterone system in healthy female volunteers. Gynecol. Endocrinol. 2006; 14: 204-13.
  14. Oelkers W.Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol. Cell. Endocrinol. 2004; 17 (1-2): 255-61.
  15. Prilepskaya V.N., Mezhevitinova E.A., Nazarov N.M., Novikova E.P., Sasunova R.A. Therapeutic possibilities of modern hormonal contraception. Emphasis on drospirenon containing drugs connection with a new dosing schedule. Gynecology, 2012; 1: 42-45.
  16. Rapkin A.J., Winer S.A. The pharmacologic management of premenstrual dysphoric disorder. Expert Opin. Pharmacother. 2008; 9: 1-17.
  17. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2008; 61 (1-2): 151-7.
  18. Steiner M., Pearlstein T., Cohen L.S., Endicott J., Kornstein S.G., Roberts C.et al. Expert guidelines for the treatment of severe PMS, PMDD, and co morbidities: the role of SSRIs. J. Womens Health (Larchmt). 2006; 15: 57-69.
  19. Tuccori M., Testi A., Antonioli L., Fornai M., Montagnani S., Ghisu N. et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants: a review. Clin. Ther. 2009; 31: 1426-53.
  20. Verma R.K., Chellappan D.K., Pandey A.K.Review on treatment of premenstrual syndrome: from conventional to alternative approach. J. Basic Clin. Physiol. Pharmacol. 2014; Mar 12.
  21. World Health Organization (WHO). International classification of diseases. 10th ed. Geneva: WHO; 1996.

file

download